In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

MeSH terms

• Androgen Antagonists / therapeutic use
• Antineoplastic Agents / therapeutic use*
• Clinical Trials as Topic
• Docetaxel
• Humans
• Male
• Patient Selection*
• Prognosis
• Prostatic Neoplasms / drug therapy*
• Prostatic Neoplasms / mortality
• Prostatic Neoplasms / secondary*
• Survival Rate
• Taxoids / therapeutic use*